Figure 2.

Comparison of gastric cancer staging and related indicators. In this study, statistics of pain VAS scores for both groups were entered into Excel software by the first and corresponding authors, respectively, and measures of gastrin-17, CEA, CA199, PGI, and PGI/PGII were tested for inclusion by the Shapiro-Wilk method of mean ± standard deviation. And independent sample or paired sample t-tests were implemented between or within groups, and HP-positive rate count data were expressed as whole numbers and found by chi-square test. Higher clinical stage of gastric cancer resulted in higher serum gastrin-17, CEA, and CA199 levels and lower PGI levels, all with statistically significant differences in comparison (P < 0.05). However, the differences in PGI/PGII and HP-positive rates were not statistically significant in patients with different gastric cancer stages (P > 0.05).